Introduction
Several radiologically defined features of skeletal muscle have been associated with clinical outcomes in patients with cancer. Reduced muscle mass (i.e. sarcopenia), loss of muscle mass over time, and reduced muscle radiodensity are related to mortality, shorter progression-free survival, chemotherapy toxicity, and complications of cancer surger. [1] [2] [3] [4] In light of the associations between muscle and outcomes, researchers are increasingly investigating the pathophysiology of muscle abnormalities [5] [6] [7] and attempting to relate the findings to the much broader base of knowledge that exists from research in animal models. Muscle may be obtained from cancer patients by percutaneous biopsy as well as intraoperatively during cancer surgery. Clinical data aligned with the biopsy provides a comprehensive approach to understand cancer cachexia from the vantage point of muscle wasting. Evaluation of human muscle contributes significantly to the understanding of molecular mechanisms in a variety of primary pathologies of skeletal muscle.
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Biopsy and tissue manipulation techniques can induce changes in the muscle that alter enzyme activity, metabolite concentrations, and protein metabolism.
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Also, patient characteristics such as age, sex, cancer type, co-morbidities, and medications (including chemotherapy) taken at the time of biopsy collection are known factors that influence muscle metabolism. [13] [14] [15] [16] [17] These methodological issues pose limitations in the reliability, interpretation, and comparability of the findings on muscle biopsies in patients with cancer. Therefore, our first aim was to conduct a state-of-the-science review of the literature on muscle biopsy in cancer patients. This type of review retains many features of a systematic review except that studies are not excluded on the basis of a quality assessment and thus presents a broader search of the literature. An associated aim was to provide recommendations of components to consider when evaluating and reporting results of muscle biopsies from cancer patients.
The second aim of this study was to evaluate sources of variation in the muscle biopsy material to better understand the risk of sampling bias, to determine variance and effect size to enable sample size calculations, and to determine the possible consequences of sexual dimorphism and age as confounders using a relatively well-powered sample (n = 190). Our research group has experience in the radiological characterization of muscle 2, 18, 19 and skeletal muscle morphology, cell biology, and biochemistry. 7, [20] [21] [22] Our collaborative effort with hepatopancreatobiliary cancer surgeons has enabled muscle biobanking and exploration of muscle biology within large populations. We have published studies on muscle expression of mRNA, microRNA, and alternative splice variants, 20, 21, 23 alongside specific and precise measures of muscle mass, radiodensity, and muscle loss.
Materials and methods

Literature review
A state-of-the-science review 24 is a broad search of the literature that includes all studies in a particular area. Our review protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 25 guidelines to reduce bias ( Figure 1 ). Articles indexed in SCOPUS from 1 January 1900 to 16 August 2018 were queried to capture reports on skeletal muscle biopsies from cancer patients. Review articles and studies on experimental models, laboratory animals, non-cancer populations, or those not employing muscle biopsies were excluded. Bibliographies of identified articles were hand searched to find additional relevant publications. There were no exclusion criteria regarding number of patients and type of study (retrospective, prospective, or cross sectional). Data were extracted from the result sections, tables, and figures of each article. As we did not aggregate the data, no additional data were contributed from the investigators. Two reviewers independently assessed each of the included studies, and disagreements were resolved by consensus. A score for study quality was given using assessment tools provided by the National Heart, Lung and Blood Institute (NIH-U.S. Department of Health & Human Services) for cross-sectional, cohort, case-control, randomized control trials and before-after studies. The Newcastle-Ottawa scale modified for cross-sectional studies 26 was used to give a bias score based on the (i) representativeness, (ii) size, and (iii) non-respondent report.
any incremental discomfort or risk, as the surgery is inherently invasive. All patients were either diagnosed as having cancer or were suspected of having cancer due to their symptoms and radiological assessments such as computed tomography (CT) imaging. The study cohort and conditions for acquisition of muscle samples have been described previously. 23 Briefly, rectus abdominis (0.5-3 g) samples were collected during open abdominal surgery scheduled as part of their clinical care. Upper abdominal transverse incision was performed, and muscle biopsy was obtained at opening by sharp dissection, without the use of electrocautery.
Computed tomography image analysis
Digital axial CT scans performed preoperatively and used to plan surgery were used to quantify skeletal muscle crosssectional area (CSA, cm 2 ) as in our prior work. 18, 27 Measures with CT have excellent precision (precision error values of 1.5%). 28 Briefly, images at the 3rd lumbar vertebra (L3) were analysed for total L3-CSA within a specified Hounsfield unit (HU) range (À29 to +150) using Slice-O-Matic software (v.4.3, Tomovision, Magog, Canada). Muscle area was normalized for stature and reported as skeletal muscle index (SMI, cm 2 /m 2 ). Mean radiodensity (HU) was also reported. Adipose tissue CSA at L3 was calculated in a HU range of À150 to À50 and À190 to À30, for visceral and subcutaneous adipose tissue, respectively. 28 The distribution of SMI of the patients providing biopsy for this study was compared with a previously described large cohort of oncology patients (n = 1473) to confirm that the population sampled is representative of muscle mass distribution and mean values for our population ( Figure 2 for analysis of gene expression, and myosin heavy chain (MyHC) by electrophoresis was immediately frozen in liquid nitrogen in the operating room prior to being transported to the lab for storage in liquid nitrogen until analysis. The other piece of the biopsy to be used for microscopy was transported on ice to the laboratory within 20 to 30 min. For morphological preservation, isopentane (2-methylbutane, C 5 H 12 ) was cooled at À160°C in liquid nitrogen for 20 min or until the appearance of a thick frozen layer at the bottom of the container. A piece of muscle was oriented for transverse section and delicately placed on aluminum foil. Tissue was submerged in isopentane for 20 s, and aluminum foil was turned upside down to allow full exposure of the muscle section. After submersion, tissue was wrapped and left in liquid nitrogen for 5 min. Information about surgery date, time, and sample reception was documented.
Immunofluorescence: fibre types, laminin/dystrophin, and nuclear stain
Muscle serial sections (10 μm) were cryosectioned (cryostat Leica model CM300) transversely at À22°C and stored at À80°C until staining. MyHC I, IID, and IIA were determined as previously described. 30 Primary and secondary antibodies are described in Supporting Information, Table S1 . After the secondary antibody application, a nuclear stain (4',6-diamidino-2-phenylindole) was added for 2 min and washed. Slides (Apex TM superior adhesive slides, Leica biosystems) were mounted, covered, and let dry for 12 h. Images for tissue sections were acquired using a 20X/0.85 oil lens with a spinning disk confocal microscope (Quorum Wave FX Spinning Disc Confocal System-Quorum technologies). Individual Z-stacked images were assembled to create a composite image of a whole tissue cross section. Tissue images were capture and analysed with Volocity 6.3 software (PerkinElmer, Waltham, MA, USA). A software script was established to identify muscle fibres types (I, I/IIA, IIA, IIA/D, and D) using intensity of the MyHC stains and quantified automatically by the software. Mean muscle fibre area (μm 2 ) was calculated by the detection of membrane (laminin/dystrophin antibody) fluorescence of muscle fibres in a cross section. Percentage of fibres with centralized nuclei was manually assessed by selecting muscle fibres with mispositioned nuclei (clearly separated from sarcolemma, equidistant, or not) in a tissue cross section.
Electrophoretic analysis of myosin heavy chain isoform content
Semi-quantitative MyHC isoform analyses were completed on frozen rectus abdominis using western blotting as previously described. [30] [31] [32] All three of the adult MyHC isoforms (I, IIA, and IID) were clearly visible on all gels and reliably quantified in at least triplicate by integrated densitometry (Syngene ChemiGenius, GeneTools, Syngene).
Triglyceride content analysis
A piece of biopsy (50 mg) was ground using a frozen pestle and mortar without letting the tissue thaw. Ground tissue was homogenized in a 1.6 mL calcium chloride (CaCl2; 0.025%) solution with glass beads (0.5 mm diameter; FastPrep ®-24, MP Biomedicals, Santa Ana, CA, USA) in 20 s intervals for 1 min. Samples were placed on ice for 15 s between each homogenization interval. A modified Folch method was used to extract lipids using chloroform/ methanol (2:1, vol/vol) as previously described. 33, 34 The triglyceride (TG) fraction was isolated on G-plates and the TG band was identified and scraped. An internal standard C15:0 (10.2 mg/100 mL hexane) was added, followed by saponification and methylation. Samples were analysed using gas liquid chromatography (flame ionization detector) on a Varian 3900 (Varian Instruments, Georgetown, ON, Canada). Quantity of fatty acids within the TG fraction was calculated by comparison with the known concentration of the internal standard and sum of all fatty acids was reported as total TG.
Gene expression: microarray
Microarray was conducted as previously described. 23 The data have been deposited in the U.S. National Center for Biotechnology Information Gene Expression Omnibus25 and are accessible through GEO series accession number GSE41726.
Statistical analysis
Statistical analyses were conducted in IBM® SPSS ® software, version 24. A test for normal distribution was applied to the continuous variables. Descriptive statistics were reported as mean ± standard deviation. Comparisons between groups were conducted using independent t-test or Mann-Whitney U according to the variable normal distribution and χ 2 test for categorical variables. Statistical significance was considered at P values less than 0.05 (two-sided).
Results
Literature review
A total of 59 articles reporting analysis of skeletal muscle in cancer populations were reviewed. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 25 flow diagram of our search strategy is shown in Figure 1 . Table 1 includes all of the extracted data as well as scores for sampling bias (Newcastle-Ottawa scale) and study quality assessments (NIH). In general, the study quality rated as low for the majority of studies ( Table 1) . Applying the Newcastle-Ottawa criteria for sampling bias revealed the majority of studies had a high risk of sampling bias with 58% of studies lacking representativeness, 96% lacking sample size justification, and no study mentioned non-respondent rate (% of population approached who declined participation). Muscles biopsied were rectus abdominis (n = 40), quadriceps (n = 20), tibialis anterior (n = 1), gastrocnemius (n = 1), pectoralis major (n = 1), sternocleidomastoid (n = 1), serratus anterior (n = 1), diaphragm (n = 1), and latissimus dorsi (n = 1), and in seven studies, more than one muscle was collected. Four studies reported evaluation of rectus abdominis from cancer patients and quadriceps for non-cancer controls, and four studies reported biopsied muscle from two or three different muscles. Gastrointestinal cancers were the most common diagnoses; 31/59 studies included patients of exclusively one cancer type: colorectal, pancreatic, gastric, breast, or prostate. Inclusion of patients with two or more cancer types was reported in 27/59 studies. Cancer stage or presence of metastasis was described in 39/59 studies. Combined data from two or more cancer stages were reported in 38/59 studies.
Study quality and design
The majority of studies were cross sectional (Supporting Information, Table S2 ). For investigation of patients with cancer cachexia, weight loss was considered as the main reference for classification. In 36 studies, weight loss was graded with varying cut points (e.g. 5%, 10%, or 15%). Time frame of weight loss was not specified in 16 of these studies ( Table 1) . Percentage weight loss ranged from 5% to 22% in weight-losing groups (Supporting Information, Table S2 ). Measures of body composition were included in 25 studies; however, these measures were used to assess muscle mass or rate of muscle wasting over time in only seven studies (Supporting Information, Table S2 ).
Total sample size in each study was generally limited (mean, n = 26; median n = 18; and range 1-134). Seventy-six per cent of studies included n ≤ 30 cancer patients; 48/59 studies included a non-cancer control group, sample size ranging from n = 3 to 41. Fifty-two studies included men and women, 5 studies only men, 1 study only women, and 2 studies did not Characterization of muscle biopsies of cancer patients Characterization of muscle biopsies of cancer patients Quality assessment score-high score means high quality.
Characterization of muscle biopsies of cancer patients specify the sex of their patients. For those studies including both sexes, 50 had an imbalance between treatment groups in the % of male and female patients, and only 3 studies matched the number of male and female participants. When reporting the results, almost all of the studies (98%) presented aggregate data from men and women. When a non-cancer control group was employed in the study, the majority of studies included control groups that went under surgical procedures (i.e. cholelithiasis and cholecystitis, ovarian cyst, inguinal hernia, laparocele, abdominal aorta aneurysm, hemangioma of liver, gallstones, and chronic pancreatitis) or healthy volunteers (Supporting Information, Table S2 ). No study defined the criteria used to select healthy volunteers. Table 1 highlights the features of the cancer groups compared with control groups. More than 54% of the studies included cancer patients with an average age of ≥65 years, and for studies involving noncancer patients as controls, 26% included patients with an average age of ≥65 years.
Most (33/59) reports failed to mention co-morbidities as a component of their exclusion criteria or patient's demographics. Commonly excluded diagnoses were diabetes, chronic obstructive pulmonary disease, liver failure, renal failure, chronic hepatitis, autoimmune diseases, and inflammatory bowel disease. Use of medications (e.g. corticosteroids, anabolic/catabolic agents, and/or beta blockers) was described in 17 studies as clinical characteristics or exclusion criteria. Prior exposure to antineoplastic drugs was reported in 14/59 studies. Inclusion of patients naïve to chemotherapy or radiotherapy was stated in 6/59 studies, two studies acknowledged the inclusion of some patients with one or fewer cycles of chemotherapy that concluded 4 weeks previous to biopsy collection.
Technical considerations Biobanking protocol and tissue manipulation
Abdominal and thoracic muscle biopsies were collected during a surgical procedure in 43 studies, with collection at the start of surgery being explicitly stated in 31 studies ( Table 2) . Presence or absence of tissue cauterization was specified in 29/43 studies. Percutaneous procedure (needle biopsy) was the main method for collection of muscles of the lower limb (n = 19 studies), open muscle biopsy technique was reported in one study, and in one study, the collection method was unspecified. For both surgical and percutaneous biopsies, removal of blood traces and/or fat/fibrotic tissue after collection was mentioned in 7/59 studies ( Table 2) .
Information provided on biopsy manipulation was limited and mainly focused on freezing and storage procedures. In 43/59 studies, immediate freezing in liquid nitrogen was reported. In only one study was it explicitly stated that freezing was done in the operating room vs. a laboratory facility. The most common temperatures for sample storage were between À70°C and À80°C; storage details were not mentioned in 11/59 studies. Details on time between biopsy and transportation to laboratory facilities and waiting periods were not reported in any study.
Rectus abdominis biological characterization
Study population Demographics and clinical data from 190 patients are provided in Table 3 . Nearly all patients (97%) who were approached consented to intraoperative biopsy, as this entails little, if any, incremental discomfort as the surgery is inherently invasive. Therefore, there was no selection bias inherent in the cohort. Typical of hepato-pancreaticbiliary case load, 88% of cancers were gastrointestinal, with the largest proportions being colorectal and pancreatic cancer. Surgical procedures included hepatectomy, liver metastasectomy, pancreatectomy, Whipple procedure, bile duct resection, cholecystectomy, colectomy, and gastrectomy. Metastasis was present in 50% of the patients. Most of the patients were naïve to chemotherapeutic agents, 23% had exposure to chemotherapy within 2 to 4 weeks prior to the surgical procedure. The majority of patients were classified as overweight. Diabetes type II and hypertension were the most common co-morbidities. Most commonly used medications reported among the population were analgesics, anti-inflammatory, statins, glucoselowering drugs, anti-hypertensives, anti-reflux, and thyroid hormone replacement ( Table 4) .
Computed tomography image analysis Muscle L3-CSA, SMI, and muscle radiodensity of rectus abdominis and total muscle are shown in Table 5 . Sarcopenia was present in 56% of the patients, 60% (n = 97) of men and 49% (n = 42) of women. Weight history was available for 45 patients. Fifty-six per cent of patients experienced weight loss (11 ± 12% in 5 ± 12 months), and 60% of weight-losing patients were sarcopenic. Out of 44% (n = 20) weight stable patients, 70% were sarcopenic.
Sex differences
In light of the fact that most of the papers in the literature review included samples of mixed sex of varying proportions, we examined all of the biopsy features for sex differences. Sexual dimorphism was prominent in L3-CSA total lumbar muscle and RA, muscle radiodensity of RA and total muscle ( Table 5) , mean fibre CSA (Table 6) , and in expression of genes associated with muscle growth, apoptosis, and inflammation ( Table 7) . Proportions of fibre types using both quantification methods, MyHC isoforms and individual fibre types, were not different between male and female patients ( Table 6) .
For centralized nuclei assessment, the mean % of fibres with centralized nuclei was 12 ± 9% (4 to 36%) and 10 ± 8% 
Age effects
Comparison of older (74 ± 4 years, n = 13) and younger (50 ± 6 years, n = 13) men revealed no differences between groups with respect to mean muscle fibre area (total, individual fibre types, or MyHC isoforms), % of individual fibre types, or % of MyHC isoforms. Age effect was evaluated in men (n = 26) by comparing mean values of a younger group vs. an older group. No significant differences were found in relation to % of MyHC isoform content.
Skeletal muscle gene expression for genes associated with cancer cachexia Differences in genes encoding proteins commonly explored in cancer-muscle wasting are summarized in Table 7 (also see Supporting Information, Table S3 ). Atrophy, autophagy, apoptosis, muscle growth, and inflammation genes were selected based on reviewed literature on muscle atrophy in cancer. 
Discussion
There is a perceived need to understand the human biology of cancer-associated muscle atrophy and to frame it in the context of our larger understanding of experimental findings. 6, 22, [109] [110] [111] The emergent literature on human muscle biopsies has been generated with that intent but has a number of substantial limitations within the study design as well as procedures for collection and preparation of the biopsy material. At the same time, there is substantial opportunity for collaboration between cancer surgeons and researchers to obtain intraoperative biopsies with a high rate of patient consent and the additional capability to describe the muscles of these patients with precise radiological metrics. Agreement to a set of standardized procedures and reporting will enhance the consistency, reliability, and comparability of future research in this area. Evaluation of human rectus abdominis muscle presents the expected variation in several measures that may be of interest for emerging studies in this area.
Study quality and design
The quality of the studies reporting on biopsy material to characterize varying features of muscle biology was uniformly low. Quality assessment tools revealed several inconsistencies in sample selection strategies, study design, data collection, and analysis in the existing literature. Bias assessment of sample selection exposed a clear absence of sample representativeness in 59% of studies and lack of sample size justification in 96% of studies. In 75% of the studies reviewed, samples from a relatively small number of participants (n = 
<0.001
Differences between men and women were analysed by independent t-test (continuous variables) and χ 2 test (categorical variables). BMI, body mass index. Other: adrenal gland, skin, kidney, mesothelium, lymphoma, melanoma, chronic lymphocytic leukemia, prostate, ovary, uterus, head, and neck. Characterization of muscle biopsies of cancer patients ≤30) were evaluated without accounting for age or sex variation.
The majority of published studies use weight loss (vs. weight stability) to define cachexia. This approach is limited by not accounting for the characteristics of muscle (muscle mass or change in muscle over time), which are the clinically relevant features related to cancer outcomes. Indeed, weight stable patients may well be losing muscle over time 112 and they can also be profoundly sarcopenic. 2, 27 Weight loss was the most commonly used criteria for cancer cachexia assessment; however, application of this measure alone poses major concerns in misclassification and unintended exclusion of cachectic patients. Many studies were published prior to the widespread use of CT images to quantify muscle, as well as prior to the publication of the international cachexia consensus, which defines muscle mass as a diagnostic criterion for cachexia. The premise of using weight loss when muscle is being evaluated is erroneous. Muscle wasting can be experienced by patients with less than 5% weight loss. 112 Also, the arbitrary selection of weight loss percentage and time frame in different studies complicates the comparison of results between studies. In the cohort of patients we evaluated, 70% of weight stable patients and 60% of weight-losing patients were sarcopenic. Therefore, assessment of muscle mass is essential, and this can be easily achieved through the secondary analysis of CT images used to plan the surgery. Percentage of patients prescribed this medication out of a total of 190 patients who had a medical history available with information provided on current medication use. Values reported in mean ± SD (range). CSA, cross-seccional area; L3, 3rd Lumbar vertebra. Characterization of muscle biopsies of cancer patients Some authors reported mortality-defined cutpoints to define sarcopenia according to age and sex of a reference population 27, 113 and these have been secondarily used by other authors. 114 Caution should be used in applying these cutpoints to define sarcopenia in patients undergoing muscle biopsy, and these may not necessarily reflect the population from which biopsies are evaluated. 114 Here, we suggest to use CT to quantify muscle features for the overall population from which the biopsy sampling is done. In this way, patients providing biopsy for our study are clearly representative of the entire L3 SMI distribution of our regional population (Alberta, Canada) ( Figure 2 ). This representation eliminates the possibility of sampling bias. It also allows each patients' SMI to be ranked within the population distribution overall as well as compared with values available for healthy young individuals.
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Age and sex differences exist at the level of muscle function, biochemistry/metabolism, and mass.
14,17,116 The majority of studies reported combined data from both sexes without acknowledging sexual dimorphisms. Age was generally not accounted for. In the first 40 years of life, muscle mass is relatively stable in both men and women, and then it begins to decline; however, the rate of loss is slower in women than in men. 62 In our sample, differences between men and women were observed for muscle fibre area, SMI, and muscle radiodensity. Sexual dimorphism in gene expression was not limited to a particular pathway or function but was identified in growth (AKT1, FOXO1, MSTN, PAX7, and TGFα1), apoptosis (CASP9), and inflammation (TNF and STAT3). In relation to the age effect, we did not find any significant differences in mean muscle fibre area and proportion of fibre types when comparing young vs. old male cancer patients; this could be potentially explained by the narrow age range in our study. Differences between young (18 to 48 years) and older (66 to 99 years) participants 117 have been reported for fibre type distribution in rectus abdominis and vastus lateralis. Therefore, age differences and sexual dimorphism must be acknowledged when comparing, reporting, and interpreting muscle characteristics.
Here, we present many characteristics of human rectus abdominis muscle. We obtained a detailed analysis of its radiological features, for the first time. Our analysis of fibre . Muscle gene expression and TG content levels as presented here are new information about rectus abdominis. Future work on rectus abdominis can be usefully planned, using this base of information. The majority of evidence to date ( Table 1 ) on muscle from cancer patients is coming from rectus abdominis. Due to the unique characteristics of each muscle type, we suggest that future researchers identify candidate muscles for intensive research using the principle that the muscle(s) most often transected in cancer surgeries would be the greatest resource. This can be decided in function of the common surgical approaches. Thus, over time, a large base of evidence may be obtained from latissimus dorsi, serratus anterior, or intercostal muscle (e.g.) from thoracic cancer surgeries.
A key component of case-control studies is to provide details of the control group relative to the research question. However, this is rarely done in the literature that we reviewed. 20, 21 Detailed clinical characterization of non-cancer controls is usually missing, and assumption of a healthier status of the control group when compared with cancer patients is common. In many cases, the comparator group is a noncancer surgical patient population; however, there is no documentation provided around diagnosis or medications. Presumably, healthy volunteers could have underlying comorbid conditions or be taking medications that impact skeletal muscle. Co-morbidities and use of medications were not generally mentioned either for patients undergoing noncancer surgery or 'healthy' volunteers recruited outside the clinical setting. Approximately 60% of people diagnosed with malignancy are 65 years and older. 13 Prevalence of comorbidity in cancer population ranges from 30% to 50% depending on type of cancer 19 and a patient with history of cancer has on average three co-morbidities. 118, 119 Diabetes and hypertension were the most common conditions in our patient population, but cardiovascular disorders and mental health problems are also prevalent in the cancer population. 13, 19 These chronic conditions and medications taken to control them can independently affect muscle physiology 15, 106, [120] [121] [122] [123] [124] [125] [126] [127] [128] (Table 4) . COX inhibitors, statins, biguanides, proton pump inhibitors, and thyroid hormones were the most common medications prescribed in our patient population apart from those prescribed during cancer treatment. Therefore, it is important that for both the cancer group and 'control' groups have a detailed medical history that captures diagnosis of other conditions and medications. In addition to drugs prescribed for management of co-morbid conditions, antineoplastic treatment previous to tissue biopsy is also a relevant event that may impact interpretation of results as the long-lasting effects in the muscle are unknown.
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Technical considerations
We suggest recommendations for minimum procedures to follow in biobanking practices, tissue manipulation, and patient characterization to enhance the consistency, reliability, and comparability of future research ( Table 8) . Acknowledgement of differences between muscle groups is essential when comparing and interpreting results. RA is commonly collected in patients with gastrointestinal disease due to its practicality in relation to the surgical incision while maintaining patient burden to the essential minimum. Its broad extension in the abdominal area enables for collection of muscle tissue from a variety of locations 136 ; however, no one has demonstrated how homogeneous the RA is in relation to the biopsy site. On the other hand, that studies collecting different muscles must avoid comparing or combining data of more than one muscle. Most researchers did not report on surgical procedures and muscle biopsy collection, transport, and processing of the samples, each of which can impact on the morphological and molecular profile of the biopsy. 10, 139, 140 Collecting abdominal muscle biopsies at the start of the surgical procedure and avoidance of electrocautery is strongly recommended to reduce variations associated with the surgical trauma, variable duration of surgery, and intraoperative effect of anaesthetics. 10, 11, [141] [142] [143] [144] Skeletal muscle collected at the start and end of a surgery expresses differences in genes associated with inflammation, growth differentiation, and transcription factors. 142 For percutaneous biopsies, the Bergstrom protocol is a well-developed method with several adjustments to improve the quality of the muscle biopsies. 145, 146 Procedures followed after biopsy collection must also be detailed as sample preservation and storage impacts on muscle integrity and potentially interpretation of the results. Lastly, the numbers of medical conditions and drugs taken by patients in this sample are important and all of these and their different combinations may have an impact on specific aspects of muscle biology. As much as possible, we recommend to annotate the presence of co-morbidities and medications in patients consenting to biopsy. Overall, the literature review reveals a high risk of sampling bias and poorly characterized patient populations. These features make reliable comparison between studies and aggregation of data challenging. Muscle biopsy preparation and biobanking practices are also variable between studies. Data from an unbiased sample of 190 patients present a variety of measures of interest on rectus abdominis to provide a point of reference for researchers exploring biological characteristics of this muscle. Continued collaboration between researchers and cancer surgeons would enable a more complete understanding of mechanisms of cancer-associated muscle atrophy.
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